GlassScriptPhysician profile
Tejwant Dhillon
NPI 1356395800
$2,119.47
in general payments reported to CMS, 2019-2025
20 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $345 · 2021: $284 · 2022: $258 · 2023: $196 · 2024: $97.71 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $646.22 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $276.99 | 2019-2023 | Farxiga |
| Abiomed | $259.82 | 2021-2022 | |
| Amgen INC. | $219.60 | 2019-2023 | Repatha |
| Shockwave Medical, INC | $136.91 | 2021 | |
| Zimmer Biomet Holdings, INC. | $108.80 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.32 | 2019-2020 | |
| Biotronik INC. | $72.59 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.31 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $42.86 | 2019 | |
| Cardiovascular Systems INC. | $36.14 | 2022 | |
| Penumbra, INC. | $35.61 | 2025 | Penumbra System, Indigo System |
| Actelion Pharmaceuticals US, INC. | $31.34 | 2019 | |
| Pfizer INC. | $22.63 | 2019 | |
| Medtronic Vascular, INC. | $20.37 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $18.67 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.59 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.16 | 2019 | |
| Medtronic, INC. | $16.12 | 2025 | Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $14.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejwant Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.